Literature DB >> 17714759

The impact of large sections on the study of in situ and invasive duct carcinoma of the breast.

Maria P Foschini1, Federica Flamminio, Rossella Miglio, Daniela G Calò, Maria C Cucchi, Riccardo Masetti, Vincenzo Eusebi.   

Abstract

Large histologic sections (LHSs) are increasingly used in the study of normal and neoplastic breast tissue. LHSs allow the direct visualization of a large part of the breast glandular tree. Accordingly, LHSs have shown that in situ and invasive lobular carcinoma is a multilobar (and hence multifocal) neoplastic lesion in more than 50% of the cases, and that poorly differentiated duct carcinoma in situ (DCIS grade 3) is frequently unifocal, whereas it is often multifocal when the in situ lesion is a well-differentiated type (DCIS grade 1). Forty-five mastectomies were studied with large sections. Mastectomies were performed when quadrantectomy did not guarantee radical excision of the tumor with adequate cosmesis because of the large size of the lesion or because the neoplastic lesion was located below the nipple. Excluded were cases of lobular neoplasia or invasive lobular carcinoma, because they were reported separately, and cases of mastectomies performed for sarcoma or recurrent phyllodes tumor. All cases had undergone a preoperative diagnostic procedure (fine needle aspiration), and the relative positive material was reviewed. All 45 cases showed in situ duct carcinoma and 37 showed evidence of invasive duct carcinoma. Forty-two cases of DCIS were multifocal, whereas only 4 invasive duct carcinoma were shown as multifocal. When DCIS lesions were subdivided into 3 grades, no statistical significance was seen among the 3 groups of DCIS in regard to multifocality. Nevertheless, DCIS grade 1 was a widespread condition involving more than one lobe and quadrant, whereas DCIS grades 2 and 3 appeared more localized. DCIS grade 1 was more similar to that previously observed in lobular in situ neoplasia/lobular in situ carcinoma. In 66.6% of the cases, DCIS foci were found within the invasive areas, indicating a more than fortuitous occurrence (2-sided P=.0357).

Entities:  

Mesh:

Year:  2007        PMID: 17714759     DOI: 10.1016/j.humpath.2007.04.007

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  7 in total

Review 1.  Are columnar cell lesions the earliest histologically detectable non-obligate precursor of breast cancer?

Authors:  Gulisa Turashvili; Malcolm Hayes; Blake Gilks; Peter Watson; Samuel Aparicio
Journal:  Virchows Arch       Date:  2008-04-24       Impact factor: 4.064

Review 2.  Radiological-pathological correlation in diagnosing breast carcinoma: the role of pathology in the multimodality era.

Authors:  Tibor Tot; Maria Gere
Journal:  Pathol Oncol Res       Date:  2008-06-03       Impact factor: 3.201

3.  The subgross morphology of breast carcinomas: a single-institution series of 2033 consecutive cases documented in large-format histology slides.

Authors:  Tibor Tot; Maria Gere; Syster Hofmeyer; Annette Bauer; Ulrika Pellas
Journal:  Virchows Arch       Date:  2019-08-13       Impact factor: 4.064

4.  Comparison of the subgross distribution of the lesions in invasive ductal and lobular carcinomas of the breast: a large-format histology study.

Authors:  Syster Hofmeyer; Gyula Pekár; Mária Gere; Miklós Tarján; Dan Hellberg; Tibor Tot
Journal:  Int J Breast Cancer       Date:  2012-10-14

5.  The role of large-format histopathology in assessing subgross morphological prognostic parameters: a single institution report of 1000 consecutive breast cancer cases.

Authors:  Tibor Tot
Journal:  Int J Breast Cancer       Date:  2012-10-21

6.  The value of large sections in surgical pathology.

Authors:  Maria P Foschini; Chiara Baldovini; Yuko Ishikawa; Vincenzo Eusebi
Journal:  Int J Breast Cancer       Date:  2012-11-21

7.  Imaging-assisted large-format breast pathology: program rationale and development in a nonprofit health system in the United States.

Authors:  F Lee Tucker
Journal:  Int J Breast Cancer       Date:  2012-12-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.